Marker Therapeutics (MRKR) Common Equity (2010 - 2026)

Marker Therapeutics (MRKR) has reported Common Equity for 17 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 15.97% year-over-year to $12.2 million in Q2 2026; TTM through Jun 2026 was $12.2 million, a 15.97% increase from a year earlier, with the FY2025 full-year figure at $16.8 million, down 9.49% from the prior year.
• Common Equity was $12.2 million for Q2 2026 at Marker Therapeutics, down from $13.8 million in the prior quarter.
• Over five years, Common Equity peaked at $35.7 million in Q1 2022 and troughed at $7.4 million in Q3 2024.
• A 5-year average of $17.0 million and a median of $16.3 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 56.77% in 2022 and surged 146.84% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $19.6 million in 2022, then declined by 28.31% to $14.1 million in 2023, then jumped by 32.06% to $18.6 million in 2024, then dropped by 9.49% to $16.8 million in 2025, then dropped by 27.57% to $12.2 million in 2026.
• The last three Common Equity figures came in at $12.2 million (Q2 2026), $13.8 million (Q1 2026), and $16.8 million (Q4 2025), per Business Quant data.